

Health Resources and Services Administration (HRSA) will publish periodic summaries of proposed projects being developed for submission to OMB under the Paperwork Reduction Act of 1995. To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, call the HRSA Reports Clearance Officer on (301) 443-1129.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the

burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Projects

1. Loan Information System Records for the DHHS and DHUD Hospital Mortgage Insurance, Guarantee, and Direct Loan Programs (OMB No. 0915-0174)—Extension, no change—The Division of Facilities Loans within the Health Resources and Services Administration monitors outstanding direct and guaranteed loans made under Section 621 of Title VI and Section 1601 of Title XVI of the Public Health Service Act, as well as loans insured under the Section 242 Hospital Mortgage Insurance Program of the Fair Housing Act. These programs were designed to

aid construction and modernization of health care facilities by increasing the access of facilities to capital through the assumption of the mortgage credit risk by the Federal Government.

Operating statistics and financial information are collected annually from hospitals with mortgages that are insured under these programs. The information is used to monitor the financial stability of the hospitals to protect the Federal investment in these facilities. The form used for the data collection is the Hospital Facility Data Abstract. No changes in the form are proposed. Because of the relatively small level of effort associated with submitting this report, there are no plans to develop a system for electronic transmission of the data. The estimate of annual burden hours is as follows:

Form	No. of respondents	Responses per respondent	Hours per response	Total hour burden
Hospital Facility Data Abstract	250 hospitals	1	1 hour	250 hours.

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14-36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: January 2, 1997.

J. Henry Montes,

Director, Office of Policy and Information Coordination.

[FR Doc. 97-424 Filed 1-7-97; 8:45 am]

BILLING CODE 4160-15-P

National Institutes of Health

Submission for OMB Review; Comment Request; Pilot Research for Epidemiologic Studies of Migrant and Seasonal Farmworkers

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National

Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on October 24, 1996, page 55159, and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, any information collection that has been extended, revised, or implemented after October 1, 1995, unless it displays a currently valid OMB control number.

Proposed Collection

Title: Pilot Research for Epidemiologic Studies of Migrant and Seasonal Farmworkers. **Type of Information Collection Request:** New.

Need and Use of Information Collection: A pilot study will be conducted to evaluate the ability to trace farmworkers over extended periods of time, to determine cancer diagnosis and treatment patterns among migrant and seasonal farmworkers, and to assess the reliability of farm work histories from farmworkers and from their spouses. The information will be used by the NCI to identify the most appropriate study design, case ascertainment procedures, and exposure assessment methods for a full-scale epidemiologic study of cancer among migrant and seasonal farmworkers. Determining the feasibility of using automated data collection techniques to obtain occupational histories from farmworkers will be part of this project. **Frequency of Response:** One-time study. **Affected public:** Individuals or households. **Type of Respondents:** Farmworkers and relatives. The annual reporting burden is as follows:

Type of respondents	Estimated No. of respondents	Estimated No. of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Farmworkers	78	1.0	.333	26
Farmworkers with family history of cancer	67	1.0	.167	11
Farmworkers' relatives with cancer	33	1.0	.333	11
Farmworkers and spouses	53	1.2	1.000	64
Farmworker Opportunity Program Clients	13,333	1.0	.167	2,222
Total				2,334

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection or information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Shelia Hoar Zahm, Project Officer, National Cancer Institute, Executive Plaza North, Room 418, Rockville, MD 20892-7364, or call non-toll-free number (301) 496-9093, or FAX your request to (301) 402-1819, or E-mail your request, including your address, to ZahmS@epndce.nci.nih.gov.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received on or before February 7, 1997.

Dated: December 6, 1996.

Nancy L. Bliss,

OMB Project Clearance Liaison.

[FR Doc. 97-334 Filed 1-7-97; 8:45 am]

BILLING CODE 4140-01-M

National Institutes Of Health

National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Use of Antiflammins

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health is seeking licensees and/or CRADA partners for the further development and commercialization of its patent portfolio for antiflammins.

The inventions claimed in U.S. Patent No. 5,266,562 issued 30 Nov 1993, "Anti-Inflammatory Agents," are available for either exclusive or non-exclusive licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404) and/or further development under one or more CRADAs in several clinically important applications as described below in the Supplementary Information.

To speed the research, development and commercialization of this new class of drugs, the National Institutes of Health is seeking one or more license agreements and/or CRADAs with pharmaceutical or biotechnology companies in accordance with the regulations governing the transfer of Government-developed agents. Any proposal to use antiflammins in the treatment of inflammatory disease processes will be considered.

ADDRESSES: CRADA proposals and questions about this opportunity should be addressed to: Ms. Sue Patow, Office of Technology Transfer, National Heart, Lung, and Blood Institute, Building 31, Room 1B30, Bethesda, MD 20892 (301/402-5579). CRADA proposals must be received by the date specified below.

Licensing proposals and questions about this opportunity should be addressed to: Ms. Carol Lavrich, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Rockville, MD 20852 (301/496-7735 ext. 287). Respondees interested in licensing the invention will be required to submit an Application for License to Public Health Service Inventions. Respondees interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to the above patent rights in order to commercialize products arising from a CRADA agreement.

DATES: There is no deadline by which license applications must be received. CRADA proposals must be received on or before April 8, 1997.

SUPPLEMENTARY INFORMATION: Antiflammins are biologically active synthetic oligopeptides, derived from the sequence similarity between lipocortin-1 and uteroglobin, an anti-inflammatory protein. These peptides have antiphospholipase A₂ and immunomodulatory properties. Because of the great therapeutic potential of specific and potent antiflammin drugs that may be developed, scientists in several Institutes at the National Institutes of Health are examining the use of antiflammins in the treatment of Health are examining the use of antiflammins in the treatment of a

variety of inflammatory processes, including acute anterior ocular inflammation (uveitis) and psoriasis.

Dr. Chi-Cho Chan, a clinical investigator at the National Eye Institute (NEI), has an IND for the use of antiflammin 2 in acute anterior uveitis, and seven patients have previously been enrolled in a clinical trial. To date, no toxicity has been observed in patients treated with this drug. Dr. Chan and Dr. Whitcup at the NEI are interested in developing new topical formulations of antiflammins and the initiation of multicenter randomized clinical trials of antiflammins for the treatment of anterior uveitis, post-operative ocular inflammation, and allergic conjunctivitis.

Dr. John DiGiovanna, an investigator in the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is studying the use of antiflammins to treat psoriasis, a hyperproliferative inflammatory skin disease. Dr. DiGiovanna would like to continue these studies with a collaborator capable of expanding these studies to include other inflammatory skin diseases such as atopic and contact dermatitis, as well as develop animal and *in vitro* models to study the effects of antiflammins on skin.

In addition, Dr. Dimitrios T. Boumpas, also of NIAMS, is studying the use of anti-inflammatory/immunosuppressive compounds to treat psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Dr. Boumpas would like to initiate studies with a collaborator to investigate the effects of antiflammins in animal models of these diseases including toxicity studies and its use and toxicity in patients with autoimmune rheumatic diseases.

CRADA aims include the rapid publication of research results and the timely exploitation of commercial opportunities. The CRADA partner(s) will enjoy rights of first negotiation for licensing Government rights to any inventions arising under the agreement and will be expected to advance funds payable upon signing the CRADA to help defray Government expenses for patenting such inventions and other CRADA-related costs.

The role of the NEI and NIAMS in these CRADAs will be as follows:

1. Provide the Collaborator(s) with samples of the subject compounds for pharmaceutical evaluation.

2. Continue the detailed physicochemical characterization of the test compounds as well as research on their mechanism of biological action, and publish these results and provide